Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ

Monica Morrow, Kimberly J. Van Zee, Lawrence J. Solin, Nehmat Houssami, Mariana Chavez-MacGregor, Jay R. Harris, Janet Horton, Shelley Hwang, Peggy L. Johnson, M. Luke Marinovich, Stuart J. Schnitt, Irene Wapnir, and Meena S. Moran

ABSTRACT

Background
Controversy exists regarding the optimal negative margin width for ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (WBRT).

Methods
A multidisciplinary consensus panel used a meta-analysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 20 studies including 7883 patients and other published literature as the evidence base for consensus.

Results
Negative margins halve the risk of IBTR compared with positive margins defined as ink on DCIS. A 2 mm margin minimizes the risk of IBTR compared with smaller negative margins. More widely clear margins do not significantly decrease IBTR compared with 2 mm margins. Negative margins less than 2 mm alone are not an indication for mastectomy, and factors known to impact rates of IBTR should be considered in determining the need for re-excision.

Conclusion
The use of a 2 mm margin as the standard for an adequate margin in DCIS treated with WBRT is associated with low rates of IBTR and has the potential to decrease re-excision rates, improve cosmetic outcome, and decrease health care costs. Clinical judgment should be used in determining the need for further surgery in patients with negative margins < 2 mm.

J Clin Oncol 34:4040-4046. © 2016 American Society of Clinical Oncology, Society of Surgical Oncology, and American Society for Radiation Oncology

INTRODUCTION

Breast-conserving therapy (BCT), defined as surgical excision of the primary tumor with a margin of surrounding normal tissue followed by whole-breast radiation therapy (WBRT), results in long-term cause-specific survival rates of greater than 95% for women with ductal carcinoma in situ (DCIS) as demonstrated in both randomized trials and observational studies. Although the addition of WBRT to surgical excision does not improve survival, it substantially reduces rates of ipsilateral breast tumor recurrence (IBTR) in patients with small, non-high-grade DCIS. In the four early randomized trials of WBRT for DCIS, microscopically clear margins defined as no ink on tumor were required in three studies, but not in the fourth. These studies provide no information on whether more widely clear margins than no ink on tumor reduce rates of IBTR in patients having BCT.

Retrospective single-institution studies have suggested that a negative margin width of 1 cm or more may eliminate the reduction in IBTR seen with WBRT, leading some to conclude that larger margins are also beneficial in patients receiving WBRT. Despite the widespread use of BCT for DCIS, there is still no consensus on what constitutes an optimal negative margin width. As a consequence, approximately one in three women attempting BCT for DCIS undergo a re-excision. Re-excisions have the potential for added discomfort, surgical complications, compromise in cosmetic outcome, additional stress for patients and families, and increased health care costs, and have been associated with conversion to bilateral mastectomy.
Since BCT was established, the landscape of DCIS management has evolved with advances in imaging and pathologic evaluation, and the availability of adjuvant endocrine therapy, resulting in a decline in IBTR rates. In view of these changes and the lack of consensus on what represents adequate negative margins in DCIS, the Society of Surgical Oncology (SSO), American Society for Radiation Oncology (ASTRO), and the American Society of Clinical Oncology (ASCO) convened a multidisciplinary margins panel (MP) to evaluate IBTR in relation to margin width. The primary question addressed was “what margin width minimizes the risk of IBTR in patients with DCIS receiving breast-conserving surgery?” The guideline developed from this consensus panel is intended to assist treating physicians and patients in the clinical decision-making process based on the best available evidence. The key findings of the guideline are summarized in Table 1.

**METHODS**

The guideline development process was funded by a Susan G. Komen grant. Committee members were chosen by their respective organizations based upon interest and expertise in DCIS management (Table 2). Processes recommended in the Institute of Medicine report “Clinical Practice Guidelines We Can Trust,” which were followed as part of the guideline development process included: (1) the development of a systematic review/study-level meta-analysis based on questions to be addressed by the MP to serve as the primary evidence base, with additional topic-specific literature reviews conducted by participants for questions not addressed in the meta-analysis; (2) the provision for each recommendation of a rating of the strength of the evidence and the strength of the recommendation; (3) the ascertainment of the level of agreement of panel members with each recommendation by vote, and the revision of recommendations to achieve greater than 90% consensus; and (4) the declaration by MP candidates of potential conflicts of interest before convening, and the obtaining of written disclosures at the consensus meeting. (The co-chairs deemed no MP members had conflicts that could influence the process/development of specific recommendations.)

The MP convened in November 2015; the resulting manuscript was approved by all panel members and externally reviewed, and feedback was incorporated. The final manuscript was approved by the SSO Executive Council, the ASTRO Board of Directors, and the ASCO Board of Directors, and endorsed by the Board of Directors of the American Society of Breast Surgeons. Patient-related materials will be available on the Susan G. Komen website (komen.org).

**Meta-Analysis**

The methodology for the systematic review/meta-analysis has been published elsewhere. Briefly, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Institute of Medicine guidelines, EMBASE, MEDLINE, PREMEDLINE, and evidence-based medicine databases were searched in October 2014 for eligible studies. A summary providing details of the methodology and statistical approaches is provided in the Appendix. Analysis was performed using two different statistical approaches. In the frequentist approach, methodology and statistical approaches is provided in the Appendix. Analysis was performed using two different statistical approaches. In the frequentist approach, a minimal negative margin (no ink on tumor or margin > 1 mm). A positive margin, defined as ink on DCIS, is associated with a significant increase in IBTR. This increased risk is not nullified by the use of WBRT.

**Positive Margins**

There is no debate that a positive margin, defined as the presence of ink from the specimen surface on ducts containing DCIS, implies a potentially incomplete resection and is associated with a higher rate of IBTR. In the Early Breast Cancer Trials’ Collaborative Group (EBCTCG) meta-analysis of randomized DCIS trials, patients with positive margins had a twofold higher IBTR risk compared with patients with negative margins despite receiving WBRT (10-year IBTR rate 24% vs 12%), and approximately 50% were invasive recurrences. The relationship between margin status and WBRT was examined in a subset analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial by central pathology review of 573 of 818 participants. The annual hazard rate for IBTR after lumpectomy alone was 8.1% for those with positive margins compared with 3.3% for patients with negative margins, reduced by WBRT to 2.7% and 1.2%, respectively. Positive margins were significantly associated with IBTR in a multivariate analysis of the long-term results of the European Organization for Research and Treatment of Cancer (EORTC) 10853 trial. In the meta-analysis of Marinovich et al using the Bayesian analytic approach, similar results were obtained. After adjustment for study-level follow up, patients with negative margins were significantly less likely to experience IBTR than patients with positive margins (OR 0.45, 95% credible interval [CrI] 0.30-0.62). Similar findings were observed in the frequentist analysis which necessitated combining positive and close margins (OR 0.53, 95% CI 0.45-0.62; P < .001). This result persisted after study-level adjustment for age, median recruitment year, grade of DCIS, use of WBRT, and use of endocrine therapy.

**Negative Margin Widths**

Margins of at least 2 mm are associated with a reduced risk of IBTR relative to narrower negative margin widths in patients receiving
**Table 1. Summary of Clinical Practice Guideline Recommendations**

| Clinical Question                                                                 | Recommendation                                                                 | Strength of Recommendation | Level of Evidence | Strength of Evidence | Consensus on Recommendation |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------|-------------------|----------------------|----------------------------|
| Are positive margins associated with an increased risk of IBTR? Can the use of WBRT mitigate this increased risk? | A positive margin, defined as ink on DCIS, is associated with a significant increase in IBTR; this increased risk is not nullified by the use of WBRT | Strong                      | Meta-analysis (patient level) of RCTs (not primary endpoint); meta-analysis (study level) of observational studies; individual RCT | Strong                        | 100%                        |
| What margin width minimizes the risk of IBTR in patients receiving WBRT?         | a. Margins of at least 2 mm are associated with a reduced risk of IBTR relative to narrower negative margin widths in patients receiving WBRT; b. the routine practice of obtaining negative margin widths wider than 2 mm is not supported by the evidence | a. Moderate                 | Meta-analysis (study level) of observational studies | a. Moderate                      | 100%                        |
| Is treatment with excision alone and widely clear margins equivalent to treatment with excision and WBRT? | Treatment with excision alone, regardless of margin width, is associated with substantially higher rates of IBTR than treatment with excision and WBRT (even in predefined low-risk patients) | Strong                      | Meta-analysis (patient level) of RCTs; individual RCT | Strong                        | 100%                        |
| What is the optimal margin width for patients treated with excision alone?        | The optimal margin width for treatment with excision alone is unknown, but should be at least 2 mm. Some evidence suggests lower rates of IBTR with margin widths wider than 2 mm | Moderate                    | Meta-analysis (study level) of observational studies; prospective single-arm studies; retrospective studies | Moderate                      | 100%                        |
| What are the effects of endocrine therapy on IBTR? Is the benefit of endocrine therapy associated with negative margin width? | Rates of IBTR are reduced with endocrine therapy, but there is no evidence of an association between endocrine therapy and negative margin width | Weak                        | RCTs               | Weak                              | 100%                        |
| Should margin widths greater than 2 mm be considered in the presence of unfavorable factors such as comedo necrosis, high grade, large size of DCIS, young patient age, negative ER status, or high risk multigene panel scores? | Multiple factors have been shown to be associated with the risk of IBTR in patients treated with and without WBRT, but there are no data addressing whether margin widths should be influenced by these factors | Weak                        | Expert opinion     | Weak                              | 100%                        |
| Should margin width be taken into consideration when determining WBRT delivery technique? | Choice of WBRT delivery technique, fractionation, and boost dose should not be dependent upon negative margin width. There is insufficient evidence to address optimal margin widths for APBI | Weak                        | Retrospective studies; expert opinion | Weak                              | 100%                        |
| Should DCIS with microinvasion be considered as invasive carcinoma or DCIS when determining optimal margin width? | DCIS with microinvasion, defined as no invasive focus > 1 cm in size, should be considered as DCIS when considering the optimal margin width | Weak                        | Expert opinion     | Weak                              | 100%                        |

Abbreviations: APBI, accelerated partial breast irradiation; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IBTR, ipsilateral breast tumor recurrence; RCT, randomized controlled trial; WBRT, whole-breast radiation therapy.

**WBRT.** The routine practice of obtaining negative margin widths wider than 2 mm is not supported by the evidence.

To address the question of optimal negative margin width, the MP considered data on the distribution of DCIS in the breast. Studies of mastectomy specimens using whole organ sectioning and radiologic-pathologic correlation have demonstrated that while most cases of DCIS are unicentric, the involvement of the segment may be multifocal, with “gaps” of uninvolved tissue between foci of DCIS. Given this, a “negative margin” does not guarantee the absence of residual DCIS in the breast.

There are also technical limitations to margin assessment which impact the relationship between margin width and IBTR. For example, margins are artifically narrower ex-vivo when specimens become flattened from lack of surrounding supportive tissue, a phenomenon exaggerated by compression for specimen radiography. Additionally, surface ink can track into deeper
portions of the specimen, posing significant challenges in determining true margin location. Finally, tumor-to-ink distance on any single slide may not be representative of the entire specimen; an “adequate” margin on one section may become positive if additional or deeper sections are examined. Two common methods for margin evaluation include sectioning perpendicular to ink (to determine tumor-to-ink width) or en-face examination of shaved margins (where any residual tumor in the shaved specimen is considered a positive margin). While an advantage of the shaved margins (where any residual tumor in the shaved specimen is considered a positive margin) is greater surface-area examination, a known disadvantage is the choice of the 2 mm threshold rather than > 0 (no ink on tumor) or 1 mm was based upon evidence of a statistically significant decrease in IBTR for 2 mm compared with 0 or 1 mm in the frequentist analysis (OR 0.51, 95% CI 0.31-0.85; P = .01) coupled with weak evidence in the Bayesian model of a reduction in IBTR with the 2 mm distance compared with smaller distances (ROR 0.72, 95% CrI 0.47-1.08). However, while the MP felt that there was evidence that the 2 mm margin optimized local control, clinical judgment must be used in determining whether patients with smaller negative margin widths (> 0 or 1 mm) require re-excision. Factors felt to be important to consider include assessment of IBTR risk (residual calcifications on postexcision mammography, extent of DCIS in proximity to margin, which margin is close [i.e., anterior excision to skin or posterior excised to pectoral fascia v margins associated with residual breast tissue], cosmetic impact of re-excision, and overall life expectancy. The conclusion that re-excision could be selectively used with margins smaller than 2 mm was influenced by the high long-term rates of local control reported in the NSABP DCIS trials which required a margin of

### Table 2. Expert Panel Members

| Panel Member                | Society       | Affiliation                     |
|-----------------------------|---------------|---------------------------------|
| Mariana Chavez-MacGregor, MD| ASCO          | University of Texas MD          |
| Jay R. Harris, MD           | ASTRO         | Harvard Medical School          |
| Janet Horton, MD            | ASTRO         | Duke University Medical Center  |
| Nehmat Houssami, MBBS, PhD  | School of Public Health | Sydney Medical School, University of Sydney |
| E. Shelley Hwang, MD, MPH   | ASBS          | Duke University Medical Center  |
| Peggy L. Johnson            | Patient Advocate | Advocate in Science, Susan G. Komen |
| M. Luke Marinovich, PhD     | School of Public Health | Yale University |
| Meena S. Moran, MD (co-chair)| ASTRO       | Yale University                  |
| Monica Morrow, MD (co-chair)| SSO          | Memorial Sloan Kettering Cancer Center |
| Stuart J. Schnitt, MD       | CAP           | Beth Israel Deacooness Medical Center and Harvard Medical School |
| Lawrence Solin, MD          | ASTRO         | Albert Einstein Healthcare Network |
| Irene Wapnir, MD            | SSO           | Stanford University             |
| Kimberly J. Van Zee, MS, MD | SSO           | Memorial Sloan Kettering Cancer Center |

Abbreviations: ASBS, American Society of Breast Surgeons; ASCO, American Society of Clinical Oncology; ASTRO, American Society for Radiation Oncology; CAP, College of American Pathology; SSO, Society of Surgical Oncology.

### Table 3. Summary of Study Characteristics Included in Meta-Analysis

| Characteristics | No. of Studies* | Median Value or Proportion Across Studies | Range of Values or Proportions Across Studies |
|----------------|----------------|------------------------------------------|----------------------------------------------|
| Age, years     | 20             | 53.7                                     | 43.0-62.1                                    |
| Type of IBTR   |                |                                          |                                              |
| DCIS           | 17             | 50.0%                                    | 0.0%-75.0                                    |
| Invasive       | 17             | 50.0%                                    | 25.0%-100.0                                  |
| Unknown        | 17             | 0.0%                                     | 0.0%-7.1                                     |
| Screen detected|                |                                          |                                              |
| Yes            | 14             | 85.8%                                    | 45.6%-100.0                                  |
| No             | 14             | 14.2%                                    | 0.0%-54.4                                    |
| Unknown        | 14             | 0.0%                                     | 0.0%-2.8                                     |
| Grade          |                |                                          |                                              |
| I              | 13             | 17.5%                                    | 1.8%-64.5                                    |
| II             | 13             | 28.0%                                    | 5.5%-45.0                                    |
| I–II           | 16             | 57.3%                                    | 7.3%-92.5                                    |
| III            | 16             | 28.4%                                    | 3.5%-45.6                                    |
| Unknown        | 16             | 9.2%                                     | 0.0%-87.3                                    |
| Hormone receptor|              |                                          |                                              |
| Positive       | 5              | 50.4%                                    | 23.0%-80.4                                   |
| Negative       | 5              | 8.7%                                     | 2.8%-14.3                                    |
| Unknown        | 5              | 40.9%                                    | 14.8%-69.8                                   |
| WBRT dose (Gy median) | 11           | 50.0%                                    | 42.5-5.0                                     |
| Radiation boost| 19             | 70.9%                                    | 0.0%-100%                                    |
| Boost dose (Gy median) | 8            | 10.0%                                    | 10.0-10.8                                    |

NOTE: Data from Marinovich et al.15

Abbreviations: DCIS, ductal carcinoma in situ; IBTR, ipsilateral breast tumor recurrence; WBRT, whole-breast radiation therapy.

*Number of studies refers to studies contributing information on the characteristic including studies with subsets of patients missing data for the characteristic.
no ink on tumor as well as the study of Van Zee et al which, after adjusting for multiple covariates, found no difference in risk between margins of ≤ 2 mm and more widely clear margins in patients receiving WBRT.

**Treatment With Excision Alone**

Treatment with excision alone, regardless of margin width, is associated with substantially higher rates of IBTR than treatment with excision and WBRT, even in predefined low-risk patients. The optimal margin width for treatment with excision alone is unknown, but should be at least 2 mm. Some evidence suggests lower rates of IBTR with margin widths wider than 2 mm.

The EBCTCG DCIS meta-analysis showed that the 10-year IBTR rate for patients treated with excision alone was higher than with excision and WBRT, both for those with negative margins (26.0% vs 12.0%, \( P < .00001 \)) and positive margins (48.3% vs 24.2%; \( P = .00004 \)). The same proportional benefit for WBRT was seen in women treated with local excision and those having large sector resections. In the Radiation Therapy Oncology Group (RTOG) 9804 trial where patients with small, mammographically detected low-to-intermediate grade DCIS and margins ≥ 3 mm were randomized to excision alone or excision plus WBRT, 7-year IBTR rates were 6.7% and 0.9% (\( P = .0003 \)), respectively. The prospective, multi-institutional Eastern Cooperative Oncology Group (ECOG) E5194 study of patients with low-risk DCIS treated with excision alone (margin width ≥ 3 mm) reported 12-year rates of IBTR of 14.4% for nonhigh grade DCIS ≤ 2.5 cm in size and 24.6% for high-grade DCIS ≤ 1 cm in size. However, IBTR rates did not differ significantly for margins < 5 mm, 5-9 mm, or ≥ 10 mm (\( P = .85 \)). A prospective single-arm study of patients with mammographically detected DCIS ≤ 2.5 cm in size reported a 10-year IBTR rate of 15.6% despite requiring margins ≥ 1 cm.⁴

In contrast, Van Zee et al found in 1266 patients treated with excision alone that 10-year IBTR rates were 16% for margins > 10 mm, and increased to 23% for margins between 2.1 and 10 mm, 27% for > 0-2 mm, and 41% for positive margins. After adjustment for multiple factors, margin width was a higher significant predictor of IBTR (\( P < .0001 \)). The MP felt that, overall, the heterogeneity of the evidence between the above-reported studies did not allow for a definitive recommendation for margin widths greater than 2 mm in patients foregoing RT.

**Endocrine Therapy**

Rates of IBTR are reduced with endocrine therapy, but there is no evidence of an association between endocrine therapy and negative margin width.

Tamoxifen reduces the incidence of both IBTR and contralateral breast cancer, but the absolute benefit is relatively small. In the NSABP B-24 trial, patients treated with lumpectomy and WBRT were randomized to tamoxifen or placebo; 25% of the population had positive or unknown margins. The 15-year IBTR rate for the placebo group was 17.4% in those with positive margins compared with 7.4% for clear margins. Adjuvant tamoxifen lowered IBTR rates among those with positive margins to levels similar to those in the negative margin cohort (17.4% placebo, 11.5% tamoxifen); conversely, there was little impact of tamoxifen in the negative margin cohort (IBTR 7.4% placebo, 7.5% tamoxifen). Hence, the MP felt that while tamoxifen decreases IBTR in patients with positive margins, there was no evidence to suggest an association between negative margin width and the benefit of endocrine therapy.

**Patient and Tumor Features**

Multiple factors have been shown to be associated with the risk of IBTR in patients treated with and without WBRT, but there are no

---

**Table 4. Margin Threshold and Ipsilateral Breast Tumor Recurrence: Bayesian Network Meta-Analysis**

| Analysis | Threshold Distance for Negative Margins Relative to Positive: Mean OR (95% CrI) Adjusted for Follow-Up |
|----------|------------------------------------------------------------------------------------------|
|          | > 0 or 1 mm | 2 mm | 3 mm | 10 mm |
| Main model (No. of patients) | 2,230 | 2,412 | 289 | 1,963 |
| Sensitivity analysis (No. of patients) | 0.45 (0.32-0.61) | 0.32 (0.21-0.48) | 0.30 (0.12-0.76) | 0.32 (0.19-0.49) |
| RT cohorts only | 1,957 | 1,851 | 272 | 1,079 |
| Sensitivity analysis (No. of patients) | 0.45 (0.34-0.66) | 0.33 (0.23-0.47) | 0.22 (0.08-0.53) | 0.37 (0.24-0.57) |
| Van Zee et al excluded | 1,781 | 1,524 | 289 | 616 |
| Sensitivity analysis (No. of patients) | 0.43 (0.31-0.57) | 0.29 (0.19-0.45) | 0.32 (0.14-0.75) | 0.27 (0.16-0.47) |
| Sensitivity analysis (No. of patients) | 2,230 | 2,412 | 289 | 1,963 |
| Sensitivity analysis (No. of patients) | 0.47 (0.34-0.63) | 0.34 (0.23-0.49) | 0.29 (0.12-0.74) | 0.36 (0.23-0.56) |
| Sensitivity analysis (No. of patients) | 2,692 | 2,555 | 322 | 2,160 |
| Sensitivity analysis (No. of patients) | 0.44 (0.30-0.63) | 0.31 (0.19-0.51) | 0.32 (0.14-0.73) | 0.20 (0.11-0.35) |

Adjustment for covariates (based on main model)

| Age | Median recruitment year | Proportion with radiotherapy | Proportion with endocrine therapy‡ | Proportion with high-grade DCIS§ |
|-----|------------------------|----------------------------|----------------------------------|-------------------------------|
| 0.46 (0.33-0.63) | 0.45 (0.31-0.62) | 0.46 (0.30-0.63) | 0.45 (0.32-0.62) | 0.45 (0.32-0.62) |
| 0.34 (0.22-0.51) | 0.31 (0.19-0.48) | 0.33 (0.22-0.49) | 0.33 (0.21-0.48) | 0.33 (0.22-0.49) |
| 0.33 (0.19-0.51) | 0.29 (0.12-0.74) | 0.29 (0.10-0.79) | 0.31 (0.17-0.57) | 0.31 (0.17-0.57) |
| 0.32 (0.20-0.51) | 0.29 (0.12-0.68) | 0.32 (0.20-0.49) | 0.32 (0.20-0.49) | 0.32 (0.20-0.49) |

**NOTE. Data from Marinovich et al.**

Abbreviations: CrI, credible interval; DCIS, ductal carcinoma in situ; OR, odds ratio; RT, radiation therapy.

‡These studies were ineligible for inclusion in the meta-analysis from Marinovich et al because of lack of summary age data (see eligibility criteria); hence sensitivity analysis reports estimates if these were included in models.

§Two studies using a 5 mm threshold were included with the 3 mm threshold group.

#19% CrI for relative odds ratio of 10 mm versus > 0 or 1 mm did not cross 1 (see meta-analysis methods).

‡Due to missing covariate information, these analyses were undertaken in a reduced number of studies (19 for endocrine therapy; 16 for high-grade DCIS).
data addressing whether margin widths should be influenced by these factors.

Young patient age has consistently been associated with IBTR, and tumor factors such as histologic pattern, comedo necrosis, and nuclear grade and size of DCIS also modify the risk of IBTR.37,26,27 More recently, unfavorable gene profile scores have also been associated with IBTR.28,29 However, there are no data addressing whether margin widths should be influenced by these factors, and this represents an appropriate area for further study.

### Radiation Delivery

Choice of WBRT delivery technique, fractionation, and boost dose should not be dependent upon negative margin width. There is insufficient evidence to address optimal margin widths for accelerated partial breast irradiation (APBI).

The vast majority of patients treated in the five prospective randomized DCIS trials of excision with or without WBRT received conventionally fractionated whole-breast RT (HWBRT) in addition to standard WBRT,4 and ≤ 10% of the patients in three of the trials received a boost.6-8 None of the randomized trials varied RT technique according to margin status, and intensity-modulated RT (IMRT) and accelerated partial breast irradiation (APBI) were not used.

There is no direct evidence from randomized trials to support the use of a boost to the primary tumor site for patients with DCIS, although in patients with invasive breast carcinoma, the long-term value of a boost in reducing IBTR has been demonstrated.30

Two ASTRO consensus guidelines have addressed technical issues in the setting of BCT. While largely focusing on invasive breast carcinoma, the ASTRO statement on HWBRT concluded there was insufficient evidence to recommend for or against HWBRT in the setting of DCIS.31 In the ASTRO statement on APBI, DCIS was placed into the “cautionary” group based on the lack of evidence from randomized trials, while noting that DCIS patients have been included in some retrospective cohort studies.32

Therefore, there is no evidence that margin width, in isolation, should determine radiation delivery technique, fractionation of WBRT, or use/dose of a boost. The MP considered the evidence base insufficient to address optimal margin width in APBI.

### DCIS in the Presence of Invasive Breast Cancer

DCIS with microinvasion, defined as no invasive focus > 1 mm in size, should be considered as DCIS when considering the optimal margin width.

There are two diagnoses for which there is overlap between the DCIS Margin Guideline and the Invasive Cancer Margin Guideline35: DCIS with microinvasion (DCIS-M) and invasive carcinoma associated with DCIS (extensive intraductal component [EIC] or lesser amounts of scattered DCIS). In DCIS-M, defined by the American Joint Committee on Cancer (AJCC) as the extension of cancer cells beyond the basement membrane with no focus more than 0.1 cm in greatest dimension,34 small retrospective studies suggest that rates of IBTR are similar to those seen with pure DCIS.35,36 In the absence of specific data to address margin width in DCIS-M, the MP, based on expert opinion, felt that DCIS-M should be considered as DCIS when considering the optimal margin width, given that the majority of the lesion is comprised of DCIS and that systemic therapy utilization for DCIS-M more closely reflects the treatment pattern for DCIS than for invasive carcinoma.

In contrast, when considering margin width for an invasive cancer with a DCIS component, regardless of extent, the MP felt that the invasive cancer guideline33 was applicable, primarily because the natural history and treatment of these lesions is more similar to invasive cancer than DCIS, even when the close margin contains DCIS. In particular, the vast majority of patients with invasive cancer receive systemic therapy, which remains less common for pure DCIS. The invasive cancer guideline33 did note that an EIC is a marker for a potential heavy burden of residual DCIS and that postexcision mammography, the presence of multiple close margins, and young patient age can be used to select patients who will benefit from re-excision. These statements echo the discussion of the MP regarding the use of re-excision in pure DCIS with margins < 2 mm discussed previously, and thus we believe that the guidelines are compatible.

### DISCUSSION

There are limitations to this guideline. It applies to patients with DCIS and DCIS-M treated with WBRT. The findings should not be extrapolated to DCIS patients treated with APBI or those with invasive carcinoma for whom a separate guideline has been developed.33 While studies including patients treated with and without WBRT were included in the meta-analysis, a meta-analysis of studies of treatment with excision alone was not conducted. Additionally, all of the studies included in the meta-analysis were retrospective. However, in the absence of any planned prospective randomized trials addressing the question of margin width and local recurrence, these studies represent the best available evidence for clinical decision making.

### AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at www.jco.org.

### AUTHOR CONTRIBUTIONS

Conception and design: All authors
Administrative support: Monica Morrow
Provision of study materials or patients: All authors
Collection and assembly of data: Monica Morrow, Kimberly J. Van Zee, Lawrence J. Solin, Nehmat Houssami, Mariana Chavez-MacGregor, Jay R. Harris, Janet Horton, Shelley Hwang, M. Luke Marinovich, Stuart J. Schnitt, Irene Wapnir, Meena S. Moran
Data analysis and interpretation: Monica Morrow, Kimberly J. Van Zee, Lawrence J. Solin, Nehmat Houssami, Mariana Chavez-MacGregor, Jay R. Harris, Janet Horton, Shelley Hwang, M. Luke Marinovich, Stuart J. Schnitt, Irene Wapnir, Meena S. Moran
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES

1. Correa C, McGale P, Taylor C, et al: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;162-177, 2010
2. Narod SA, Iqbal J, Giannakas V, et al: Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1:888-896, 2015
3. Worni M, Akushevich I, Greenup R, et al: Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst 107:dx263, 2015
4. McCormick B, Winter K, Hudis C, et al: RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33:709-715, 2015
5. Houghton J, George WD, Cuzick J, et al: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ in the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet 362:95-102, 2003
6. Julien JP, Bijker N, Fentiman IS, et al: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10893. Lancet 359:928-933, 2002
7. Wapnir IL, Dignam JJ, Fisher B, et al: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478-483, 2011
8. Emdin SO, Granstrand B, Ringberg A, et al: SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45:536-543, 2006
9. Silverstein MU, Lagios MD, Groshen S, et al: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455-1461, 1999
10. Azu M, Abrahamse P, Katz SJ, et al: What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol 17:558-563, 2010
11. Morrow M, Jagsi R, Alderman AK, et al: Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 302:1551-1556, 2009
12. King TA, Sakr R, Patil S, et al: Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29: 2158-2164, 2011
13. Subbedar P, Olocice C, Patil S, et al: Decreasing recurrence rates for ductal carcinoma in situ: Analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 22:3273-3281, 2015 [Erratum: Ann Surg Oncol 22: S168, 2015]
14. Greenfield S, Steinberg EP, Auerbach A, et al: Clinical practice guidelines we can trust. http://www. nationalacademies.org/hmd/Reports/2011/Clinical- Practice-Guidelines-We-Can-Trust.aspx
15. Marinovich ML, Azzi L, Macaskill P, et al: The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis. Ann Surg Oncol (in press)
16. Bland JM, Altman DG: Bayesians and frequentists. BMJ 317:1151-1160, 1998
17. Fisher ER, Costantino J, Fisher B, et al: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Intra- ductal carcinoma (ductal carcinoma in situ). Cancer 75:1310-1319, 1995
18. Donker M, Littré S, Werustsky G, et al: Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10863 randomized phase III trial. J Clin Oncol 31:4054-4059, 2013
19. Faverly DR, Burgers L, Bult P, et al: Three dimensional imaging of mammary ductal carcinoma in situ: Clinical implications. Semin Diagn Pathol 11: 193-198, 1994
20. Guidi AJ, Connolly JL, Harris JR, et al: The relationship between shaved margin and inked margin status in breast excision specimens. Cancer 79:1568-1573, 1997
21. Carter D: Margins of “lumpectomy” for breast cancer. Hurn Pathol 17:330-332, 1986
22. Van Zee KJ, Subbedar P, Olocice C, et al: Relationship between margin width and recurrence of ductal carcinoma in situ: Analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 262:623-631, 2015
23. Solin LJ, Gray R, Hughes LL, et al: Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33:3939-3944, 2015
24. Wong JS, Chen YH, Gadd MA, et al: Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 143:343-350, 2014
25. Cuzick J, Sestak I, Pinder SE, et al: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UKANZ DCIS trial. Lancet Oncol 12:21-29, 2011
26. Bijker N, Meijnen P, Petersen JL, et al: Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10893—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381-3387, 2006
27. Pinder SE, Duggan C, Ellis IO, et al: A new pathological system for grading DCIS with improved prediction of local recurrence: Results from the UKCCCR/ANZ DCIS trial. Br J Cancer 103: 94-100, 2010
28. Rakovich E, Nofech-Mozes S, Hanna W, et al: A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152:389-398, 2015
29. Solin LJ, Gray R, Baehner FL, et al: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105:701-710, 2013
30. Bartelink H, Maingon P, Poortmans P, et al: Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16:47-56, 2015
31. Smith BD, Bentzen SM, Correa CR, et al: Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 81:59-68, 2011
32. Smith BD, Arthur DW, Buchholz TA, et al: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74: 987-1001, 2009
33. Moran MS, Schnitt SJ, Giuliano AE, et al: Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507-1515, 2014
34. Edge SB, Byrd DR, Compton C, et al (eds): American Joint Committee on Cancer (AJCC) Cancer Staging Manual (ed 7). New York, NY, Springer, 2011
35. Li Y, Zhang S, Wei X, et al: The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective cohort study. Int J Surg 19:91-94, 2015
36. Panich RP, Hafty BG, Lannin D, et al: Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82:7-13, 2012

Affiliations

Monica Morrow and Kimberly J. Van Zee, Breast Service, Memorial Sloan Kettering Cancer Center, New York, NY; Lawrence J. Solin, Albert Einstein Healthcare Network, Philadelphia, PA; Mariana Chavez-MacGregor, University of Texas MD Anderson Cancer Center, Houston, TX; Jay R. Harris and Stuart J. Schnitt, Harvard Medical School, Boston, MA; Janet Horton and Shelley Hwang, Duke University Medical Center, Durham, NC; Peggy L. Johnson, Advocate in Science, Susan G. Komen, Kansas City, KS; Irene Wapnir, Stanford University School of Medicine, Stanford, CA; Meena S. Moran, Yale School of Medicine, Yale University, New Haven, CT; and Nehmat Houssami and M. Luke Marinovich, Screening and Test Evaluation Program (STEP), Sydney School of Public Health, Sydney Medical School, The University of Sydney, New South Wales, Australia.

4046 © 2016 American Society of Clinical Oncology, Society of Surgical Oncology, and American Society for Radiation Oncology JOURNAL OF CLINICAL ONCOLOGY
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Monica Morrow
No relationship to disclose

Kimberly J. Van Zee
No relationship to disclose

Lawrence J. Solin
No relationship to disclose

Nehmat Houssami
No relationship to disclose

Mariana Chavez-MacGregor
No relationship to disclose

Jay R. Harris
No relationship to disclose

Janet Horton
No relationship to disclose

Shelley Hwang
No relationship to disclose

Peggy L. Johnson
No relationship to disclose

M. Luke Marinovich
No relationship to disclose

Stuart J. Schnitt
No relationship to disclose

Irene Wapnir
No relationship to disclose

Meena S. Moran
No relationship to disclose
Appendix

Summary of Methodology for the Margins Meta-Analysis
The methods for the meta-analysis are described in full in Marinovich et al,15 and are summarized briefly below.

Study Eligibility Criteria
Eligible studies enrolled ≥ 50 women with ductal carcinoma in situ (DCIS) undergoing breast conserving surgery (BCS); allowed calculation of the crude local recurrence (LR) rate by microscopic margin status; defined negative margins by a numeric threshold; reported mean or median age; and presented mean or median follow up of ≥ 48 months.

Literature Search and Data Extraction
MEDLINE, PREMEDLINE, EMBASE, and ALL EBM REVIEWS were searched in October 2014. One investigator screened citations, with a sample independently screened by a second. Two investigators independently extracted data; disagreements were arbitrated by a third investigator.

Statistical Analysis
Frequentist models (random effects logistic meta-regression). Margins were dichotomised into positive/close versus negative margin status using one distance threshold per study (> 0 or 1 mm; 2 mm; 3 or 5 mm; 10 mm). The association between LR and margin status and distance was modeled using random effects logistic meta-regression. Odds ratios (ORs) are presented for negative relative to positive/close margins, and threshold distances relative to > 0 or 1 mm.

Bayesian models (network meta-analysis). Network meta-analysis using Mixed Treatment Comparisons used data from single or multiple thresholds within studies (when presented) to compare directly (within study) and indirectly (between studies) the probability of LR between margins categories (positive; > 0 or 1 mm; 2 mm; 3 mm; 10 mm). ORs compare negative versus positive margins, and distance categories relative to positive margins.

Assessment of covariates. All models were adjusted for study-level follow up time. Other covariates were assessed for their effect on model estimates (age; median year of recruitment; proportion of patients who received endocrine therapy; proportion with high-grade DCIS; proportion of patients receiving whole breast radiation).